Stocktwits on MSN
SLS stock in spotlight on EU expansion for cancer therapy – retail says potential catalyst for buyout
The European study is expected to enroll 40 newly diagnosed AML patients. ・Enrollment at U.S. sites is planned to begin in ...
Stocktwits on MSN
SLS stock breaches $5 level after over 3 years: Retail now eyes buyout for as much as $25B
SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...
NOSTRAND ROBERT L VAN, a director at $SLS, bought 10,000 shares of the company on 06-12-2025 for an estimated $14,800. This trade was reported by Quiver Quantitative ...
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
SELLAS Life Sciences (NASDAQ:SLS) traded sharply lower on Thursday after the New York-based biotech released interim results from its Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS), ...
SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are trading higher on Monday after initially dropping in premarket trading, reversing course as investors seem to react to new trial‑related updates ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback